Development of Oil with Healthy Properties Based on Corbella Olive Variety (HEVOOC)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Changes in carotenoids and their metabolites after each intervention with EVOO and the control intervention.
研究概览
简要总结
The consumption of the improved extra virgin olive oil (EVOO) of the Corbella variety could have a beneficial effect on the microbiota-intestine-brain axis (MGBA). Olive oil contains polyphenols that are not present in other oils, notably oleocanthal and oleacein, which behave similarly to ibuprofen and have a protective effect on some neurodegenerative diseases. The polyphenols of the oil present prebiotic characteristics, at the level of the intestinal microbiota, which metabolizes them forming bioactive metabolites that can have a modulating effect on the MGBA, improving brain health. In this study, the researchers seek to identify the benefits of the consumption of Corbella variety EVOO on MGBA in healthy participants. The overall benefit of the study would be to achieve knowledge that would allow its future applicability to prevent and improve certain diseases and in general contribute to optimal health.
详细描述
To evaluate possible effects on MGBA, a randomized, controlled, crossover nutritional trial will be conducted. Thirty healthy adult participants (between 18 and 35 years of age, with 50% male and 50% female) will be included according to the estimated sample size. Participants will consume a daily amount of 0.7 g Corbella EVOO/kg body weight plus their normal diet (experimental intervention) and 0.7 g refined olive oil (ROO)/kg body weight plus their normal diet (control intervention) for 1 month. Biological samples (plasma, peripheral blood mononuclear cells, serum, 24-hour urine, feces and saliva) will be obtained at baseline and at the end of each trial arm.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 35 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult with Body mass index (BMI) < 30 kg/m2
- •Signed informed consent
排除标准
- •Any chronic disease (e.g. cardiovascular disease, cancer or diabetes)
- •Mental disorders (e.g. depression, dementia, autism, etc.)
- •Cardiovascular alterations in cholesterol,triglycerides, glucose, etc.
- •Current smokers
- •Repeated use of antibiotics
- •Frequent use of corticoids, nonsteroidal anti-inflammatory drugs
- •Repeated use of vitamins
- •Volunteers with extreme eating habits (i.e. Atkins diet, very high protein diets, etc.)
- •Excessive alcohol consumption (>30 g/d for males and >20 g/d for females),
- •Pregnant, lactating, and postmenopausal women
结局指标
主要结局
Changes in carotenoids and their metabolites after each intervention with EVOO and the control intervention.
时间窗: Baseline and after completed each intervention (1 month)
Carotenoids and their metabolites derived from intestinal gut microbiota will be identified and quantified in human plasma, urine, feces, and saliva samples using high performance liquid chromatography (HPLC) - Linear Trap Quadrupole (LTQ) Orbitrap-MS/MS and HPLC-MS/MS techniques.
Changes in the gut microbiota after each intervention with EVOO and the control intervention.
时间窗: Baseline and after completed each intervention (1 month)
Fecal samples will be collected by the volunteers using a system for easy self-collection and stabilization of microbial DNA for gut microbiome profiling (OMNIgene - GUT). The extraction of genomic DNA from fecal samples will be carried out utilizing the DNeasy Power Kit. Subsequently, microbial profiling will employ 16 S ribosomal RNA (rRNA) sequencing to investigate microbial communities, with a specific focus on bacterial phylogeny and taxonomy.
Changes in the short-chain fatty acids in plasma and feces samples after each intervention with EVOO and the control intervention.
时间窗: Baseline and after completed each intervention (1 month)
After acidifying the fecal samples with formic acid, a quantification of short-chain fatty acids will be performed using gas chromatography by direct injection according to previously described methodology (Zhao et al., 2006).
Changes in bile acids in plasma and feces samples after each intervention with EVOO and the control intervention.
时间窗: Baseline and after completed each intervention (1 month)
Bile acids will be assayed using a validated liquid chromatography-mass spectrometry (LC-MS) method
Changes in brain-derived neurotrophic factor (BDNF) after each intervention with EVOO and the control intervention.
时间窗: Baseline and after completed each intervention (1 month)
Serum samples will be analysed for mature BDNF using a Mature BDNF Rapid ELISA kit.
Changes in cerebrovascular function after each intervention with EVOO and the control intervention.
时间窗: Baseline and after completed each intervention (1 month)
Cerebrovascular function will be measured using functional magnetic resonance imaging (FMRI), a non-invasive method for assessing brain activity. FMRI maps blood oxygenation levels in the brain and estimates changes in the blood flow that depends on metabolic function and is correlated with specific brain region activities
Changes in the polyphenols and their metabolites after each intervention with EVOO and the control intervention.
时间窗: Baseline and after completed each intervention (1 month)
Polyphenols and their metabolites derived from intestinal gut microbiota will be identified and quantified in human plasma, urine, feces, and saliva samples using high performance liquid chromatography (HPLC) - Linear Trap Quadrupole (LTQ) Orbitrap-MS/MS and HPLC-MS/MS techniques.
次要结局
- Changes in body composition after each intervention with EVOO and the control intervention.(Baseline and after completed each intervention (1 month))
- Changes in heart rate after each intervention with EVOO and the control intervention.(Baseline and after completed each intervention (1 month))
- Changes in hip circumference after each intervention with EVOO and the control intervention.(Baseline and after completed each intervention (1 month))
- Changes in physical activity after each intervention with EVOO and the control intervention.(Baseline and after completed each intervention (1 month))
- Changes in waist circumference after each intervention with EVOO and the control intervention.(Baseline and after completed each intervention (1 month))
- Changes in glucose after each intervention with EVOO and the control intervention.(Baseline and after completed each intervention (1 month))
- Assessing variations in inflammatory biomarkers post-intervention for both EVOO treatments and the control group.(Baseline and after completed each intervention (1 month))
- Changes in body mass index (BMI) after each intervention with EVOO and the control intervention.(Baseline and after completed each intervention (1 month))
- Changes in blood pressure after each intervention with EVOO and the control intervention.(Baseline and after completed each intervention (1 month))
- Changes in body weight after each intervention with EVOO and the control intervention.(Baseline and after completed each intervention (1 month))
- Changes in lipidic profile after each intervention with EVOO and the control intervention.(Baseline and after completed each intervention (1 month))
- Changes in liver function after each intervention with EVOO and the control intervention.(Baseline and after completed each intervention (1 month))
- Changes in nutrients and energy intake after each intervention with EVOO and the control intervention.(Baseline and after completed each intervention (1 month))
- Changes in quality of the diet after each intervention with EVOO and the control intervention.(Baseline and after completed each intervention (1 month))
- Changes in sleep quality after each intervention with EVOO and the control intervention(Baseline and after completed each intervention (1 month))
- Changes in inflammatory biomarkers after each intervention with EVOO and the control intervention.(Baseline and after completed each intervention (1 month))
研究者
Rosa M Lamuela-Raventós
FULL PROFESSOR
University of Barcelona